"Tumor-Free Survival" Outweighs the Side Effects of Combined Anti-EGF Therapy and Chemotherapy in Patients With NSCLC

J Thorac Oncol. 2024 Aug;19(8):1151-1154. doi: 10.1016/j.jtho.2024.05.368.

Authors

Maisam Makarem¹, Pasi A Jänne²

Affiliations

¹ Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: [email protected].

PMID: 39112002
DOI: 10.1016/j.jtho.2024.05.368

No abstract available

Publication types

Letter
Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / mortality
Carcinoma, Non-Small-Cell Lung* / pathology
Disease-Free Survival
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / mortality
Lung Neoplasms* / pathology